O	0	1	A
O	2	12	Randomized
O	13	24	Multicenter
O	25	30	Phase
O	31	33	II
O	34	39	Study
O	40	42	of
B-intervention	43	58	Docosahexaenoic
I-intervention	59	63	Acid
O	64	66	in
O	67	75	Patients
O	76	80	with
O	81	82	a
O	83	90	History
O	91	93	of
O	94	100	Breast
O	101	107	Cancer
O	107	108	,
O	109	121	Premalignant
O	122	129	Lesions
O	129	130	,
O	131	133	or
O	134	140	Benign
O	141	147	Breast
O	148	155	Disease
O	155	156	.

O	157	164	Obesity
O	164	165	,
O	166	167	a
O	168	173	cause
O	174	176	of
O	177	188	subclinical
O	189	201	inflammation
O	201	202	,
O	203	205	is
O	206	207	a
O	208	212	risk
O	213	219	factor
O	220	223	for
O	224	227	the
O	228	239	development
O	240	242	of
O	243	257	postmenopausal
O	258	264	breast
O	265	271	cancer
O	272	275	and
O	276	278	is
O	279	289	associated
O	290	294	with
O	295	301	poorer
O	302	308	cancer
O	309	317	outcomes
O	317	318	.

O	319	334	Docosahexaenoic
O	335	339	acid
O	340	341	(
O	341	344	DHA
O	344	345	)
O	345	346	,
O	347	349	an
O	350	355	omega
O	355	356	-
O	356	357	3
O	358	363	fatty
O	364	368	acid
O	368	369	,
O	370	379	possesses
O	380	384	anti
O	384	385	-
O	385	397	inflammatory
O	398	408	properties
O	408	409	.

O	410	412	We
O	413	425	hypothesized
O	426	430	that
O	431	440	treatment
O	441	445	with
O	446	449	DHA
O	450	455	would
O	456	462	reduce
O	463	466	the
O	467	477	expression
O	478	480	of
O	481	496	proinflammatory
O	497	502	genes
O	503	506	and
O	507	516	aromatase
O	516	517	,
O	518	521	the
O	522	526	rate
O	526	527	-
O	527	535	limiting
O	536	542	enzyme
O	543	546	for
O	547	555	estrogen
O	556	568	biosynthesis
O	568	569	,
O	570	572	in
O	573	579	benign
O	580	586	breast
O	587	593	tissue
O	594	596	of
O	597	607	overweight
O	607	608	/
O	608	613	obese
O	614	619	women
O	619	620	.

O	621	622	A
O	623	633	randomized
O	633	634	,
O	635	642	placebo
O	642	643	-
O	643	653	controlled
O	653	654	,
O	655	661	double
O	661	662	-
O	662	667	blind
O	668	673	phase
O	674	676	II
O	677	682	study
O	683	685	of
O	686	689	DHA
O	690	695	given
O	696	699	for
O	700	702	12
O	703	708	weeks
O	709	711	to
B-eligibility	712	722	overweight
I-eligibility	722	723	/
I-eligibility	723	728	obese
I-eligibility	729	734	women
I-eligibility	735	739	with
I-eligibility	740	741	a
I-eligibility	742	749	history
I-eligibility	750	752	of
I-eligibility	753	758	stage
I-eligibility	759	760	I
I-eligibility	760	761	-
I-eligibility	761	764	III
I-eligibility	765	771	breast
I-eligibility	772	778	cancer
I-eligibility	778	779	,
I-eligibility	780	784	DCIS
I-eligibility	784	785	/
I-eligibility	785	789	LCIS
I-eligibility	789	790	,
I-eligibility	791	796	Paget
I-eligibility	796	797	'
I-eligibility	797	798	s
I-eligibility	799	806	disease
I-eligibility	806	807	,
I-eligibility	808	810	or
I-eligibility	811	824	proliferative
I-eligibility	825	831	benign
I-eligibility	832	838	breast
I-eligibility	839	846	disease
O	847	850	was
O	851	858	carried
O	859	862	out
O	862	863	.

O	864	866	In
O	867	871	this
O	872	879	placebo
O	880	890	controlled
O	891	896	trial
O	896	897	,
O	898	901	the
O	902	909	primary
O	910	919	objective
O	920	923	was
O	924	926	to
B-outcome-Measure	927	936	determine
I-outcome-Measure	937	944	whether
I-outcome-Measure	945	948	DHA
I-outcome-Measure	949	950	(
I-outcome-Measure	950	951	1
I-outcome-Measure	951	952	,
I-outcome-Measure	952	955	000
I-outcome-Measure	956	958	mg
I-outcome-Measure	959	961	by
I-outcome-Measure	962	967	mouth
I-outcome-Measure	968	973	twice
I-outcome-Measure	974	979	daily
I-outcome-Measure	979	980	)
I-outcome-Measure	981	988	reduced
I-outcome-Measure	989	995	breast
I-outcome-Measure	996	1002	tissue
I-outcome-Measure	1003	1009	levels
I-outcome-Measure	1010	1012	of
I-outcome-Measure	1013	1016	TNF
I-outcome-Measure	1016	1017	α
O	1017	1018	.

O	1019	1028	Secondary
O	1029	1039	objectives
O	1040	1048	included
B-outcome-Measure	1049	1059	evaluation
I-outcome-Measure	1060	1062	of
I-outcome-Measure	1063	1066	the
I-outcome-Measure	1067	1073	effect
I-outcome-Measure	1074	1076	of
I-outcome-Measure	1077	1080	DHA
I-outcome-Measure	1081	1083	on
I-outcome-Measure	1084	1090	breast
I-outcome-Measure	1091	1097	tissue
I-outcome-Measure	1098	1104	levels
I-outcome-Measure	1105	1107	of
I-outcome-Measure	1108	1111	COX
I-outcome-Measure	1111	1112	-
I-outcome-Measure	1112	1113	2
I-outcome-Measure	1113	1114	,
I-outcome-Measure	1115	1118	IL1
I-outcome-Measure	1118	1119	β
I-outcome-Measure	1119	1120	,
I-outcome-Measure	1121	1130	aromatase
I-outcome-Measure	1130	1131	,
I-outcome-Measure	1132	1137	white
I-outcome-Measure	1138	1145	adipose
I-outcome-Measure	1146	1152	tissue
I-outcome-Measure	1153	1165	inflammation
I-outcome-Measure	1165	1166	,
I-outcome-Measure	1167	1170	and
I-outcome-Measure	1171	1175	gene
I-outcome-Measure	1176	1186	expression
I-outcome-Measure	1187	1189	by
I-outcome-Measure	1190	1193	RNA
I-outcome-Measure	1193	1194	-
I-outcome-Measure	1194	1197	seq
O	1197	1198	.

O	1199	1202	Red
O	1203	1208	blood
O	1209	1213	cell
O	1214	1219	fatty
O	1220	1224	acid
O	1225	1231	levels
O	1232	1236	were
O	1237	1245	measured
O	1246	1248	to
O	1249	1255	assess
O	1256	1266	compliance
O	1266	1267	.

O	1268	1272	From
O	1273	1277	July
O	1278	1282	2013
O	1283	1285	to
O	1286	1294	November
O	1295	1299	2015
O	1299	1300	,
B-total-participants	1301	1303	64
O	1304	1316	participants
O	1317	1321	were
O	1322	1332	randomized
O	1333	1336	and
O	1337	1344	treated
O	1345	1347	on
O	1348	1353	trial
O	1354	1355	(
B-intervention-participants	1355	1357	32
O	1358	1363	women
O	1364	1367	per
O	1368	1371	arm
O	1371	1372	)
O	1372	1373	.

O	1374	1383	Increased
B-outcome	1384	1390	levels
I-outcome	1391	1393	of
I-outcome	1394	1399	omega
I-outcome	1399	1400	-
I-outcome	1400	1401	3
I-outcome	1402	1407	fatty
I-outcome	1408	1413	acids
O	1414	1416	in
O	1417	1420	red
O	1421	1426	blood
O	1427	1432	cells
O	1433	1437	were
O	1438	1446	detected
O	1447	1456	following
O	1457	1466	treatment
O	1467	1471	with
O	1472	1475	DHA
O	1476	1477	(
O	1477	1478	P
O	1479	1480	<
O	1481	1482	0
O	1482	1483	.
O	1483	1486	001
O	1486	1487	)
O	1488	1491	but
O	1492	1495	not
O	1496	1503	placebo
O	1503	1504	.

O	1505	1514	Treatment
O	1515	1519	with
O	1520	1523	DHA
O	1524	1527	did
O	1528	1531	not
O	1532	1537	alter
B-outcome	1538	1544	levels
I-outcome	1545	1547	of
I-outcome	1548	1551	TNF
I-outcome	1551	1552	α
I-outcome	1553	1554	(
I-outcome	1554	1555	P
I-outcome	1556	1557	=
I-outcome	1558	1559	0
I-outcome	1559	1560	.
I-outcome	1560	1562	71
I-outcome	1562	1563	)
I-outcome	1563	1564	,
I-outcome	1565	1567	or
I-outcome	1568	1573	other
I-outcome	1574	1584	biomarkers
O	1585	1594	including
O	1595	1598	the
O	1599	1612	transcriptome
O	1613	1615	in
O	1616	1622	breast
O	1623	1630	samples
O	1630	1631	.

O	1632	1641	Treatment
O	1642	1646	with
O	1647	1650	DHA
O	1651	1654	was
B-outcome	1655	1662	overall
I-outcome	1663	1667	well
I-outcome	1667	1668	-
I-outcome	1668	1677	tolerated
O	1677	1678	.

O	1679	1687	Although
O	1688	1698	compliance
O	1699	1702	was
O	1703	1712	confirmed
O	1712	1713	,
O	1714	1716	we
O	1717	1720	did
O	1721	1724	not
O	1725	1732	observe
O	1733	1740	changes
O	1741	1743	in
O	1744	1747	the
O	1748	1754	levels
O	1755	1757	of
O	1758	1770	prespecified
O	1771	1781	biomarkers
O	1782	1784	in
O	1785	1788	the
O	1789	1795	breast
O	1796	1801	after
O	1802	1811	treatment
O	1812	1816	with
O	1817	1820	DHA
O	1821	1825	when
O	1826	1834	compared
O	1835	1839	with
O	1840	1847	placebo
O	1847	1848	.

O	1849	1855	Cancer
O	1856	1860	Prev
O	1861	1864	Res
O	1864	1865	;
O	1866	1868	11
O	1868	1869	(
O	1869	1870	4
O	1870	1871	)
O	1871	1872	;
O	1873	1876	203
O	1876	1877	-
O	1877	1879	14
O	1879	1880	.

O	1881	1882	©
O	1882	1886	2018
O	1887	1894	AACRSee
O	1895	1902	related
O	1903	1912	editorial
O	1913	1915	by
O	1916	1922	Fabian
O	1923	1926	and
O	1927	1933	Kimler
O	1933	1934	,
O	1935	1936	p
O	1936	1937	.

O	1938	1941	187
O	1941	1942	.
